PE20120553A1 - Anticuerpos anti-fgfr3 - Google Patents

Anticuerpos anti-fgfr3

Info

Publication number
PE20120553A1
PE20120553A1 PE2011001694A PE2011001694A PE20120553A1 PE 20120553 A1 PE20120553 A1 PE 20120553A1 PE 2011001694 A PE2011001694 A PE 2011001694A PE 2011001694 A PE2011001694 A PE 2011001694A PE 20120553 A1 PE20120553 A1 PE 20120553A1
Authority
PE
Peru
Prior art keywords
hvr
sequence
seq
refers
chain variable
Prior art date
Application number
PE2011001694A
Other languages
English (en)
Inventor
Avi Ashkenazi
Jing Qing
Christian Wiesmann
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42340706&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120553(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20120553A1 publication Critical patent/PE20120553A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE REFIERE A UN ANTICUERPO MONOCLONAL QUIMERICO HUMANIZADO QUE ES ANTAGONISTA ANTI-FGFR3 QUE COMPRENDE: i) HVR-H1 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 149, ii) HVR-H2 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 150, iii) HVR-H3 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 151, iv) HVR-L1 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 146, v) HVR-L2 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 147, Y vi) HVR-L3 QUE COMPRENDE LA SECUENCIA SEC ID Nº: 148; EN DONDE LA REGION VARIABLE DE CADENA PESADA COMPRENDE LA SEC ID Nº: 132 Y LA REGION VARIABLE DE CADENA LIGERA COMPRENDE LA SEC ID Nº: 133. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER DE VEJIGA, MIELOMA MULTIPLE
PE2011001694A 2009-03-25 2010-03-24 Anticuerpos anti-fgfr3 PE20120553A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16322209P 2009-03-25 2009-03-25

Publications (1)

Publication Number Publication Date
PE20120553A1 true PE20120553A1 (es) 2012-05-18

Family

ID=42340706

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001694A PE20120553A1 (es) 2009-03-25 2010-03-24 Anticuerpos anti-fgfr3

Country Status (29)

Country Link
US (10) US20100291114A1 (es)
EP (3) EP2411414B1 (es)
JP (1) JP5757534B2 (es)
KR (2) KR101830024B1 (es)
CN (2) CN104788564A (es)
AR (2) AR075939A1 (es)
AU (1) AU2010229994B2 (es)
BR (1) BRPI1006448B1 (es)
CA (1) CA2754163C (es)
CO (1) CO6450665A2 (es)
DK (2) DK2411414T3 (es)
EC (1) ECSP11011417A (es)
ES (2) ES2549769T3 (es)
HK (1) HK1167666A1 (es)
HR (2) HRP20221471T1 (es)
HU (2) HUE061117T2 (es)
IL (2) IL214433A (es)
LT (1) LT3702371T (es)
MA (1) MA33208B1 (es)
MX (2) MX2011009961A (es)
NZ (1) NZ594339A (es)
PE (1) PE20120553A1 (es)
RU (1) RU2568066C2 (es)
SG (1) SG174904A1 (es)
SI (2) SI2411414T1 (es)
TW (1) TWI507205B (es)
UA (1) UA104459C2 (es)
WO (1) WO2010111367A1 (es)
ZA (1) ZA201105574B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60233509D1 (de) 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
HUE061117T2 (hu) 2009-03-25 2023-05-28 Genentech Inc Anti-FGFR3 antitestek és eljárások alkalmazásukra
EP2766000A2 (en) 2011-10-15 2014-08-20 F.Hoffmann-La Roche Ag Scd1 antagonists for treating cancer
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
JP6188681B2 (ja) * 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
CA2880013C (en) * 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20140030259A1 (en) * 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
PL2888283T3 (pl) 2012-08-24 2019-03-29 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
MX369550B (es) * 2012-09-27 2019-11-12 Chugai Pharmaceutical Co Ltd Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
CN104903448B (zh) * 2012-11-26 2017-07-11 罗氏创新中心哥本哈根有限公司 用于调节fgfr3的表达的组合物和方法
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
LT2936153T (lt) * 2012-12-21 2019-01-25 Janssen Biotech, Inc. Jautrus daugybinis imunologinis tirpių fibroblastų augimo faktoriaus receptorių tyrimas
WO2014111744A1 (en) 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
RU2015137610A (ru) 2013-03-06 2017-04-10 Дженентек, Инк. Способы лечения и профилактики лекарственной резистентности злокачественных опухолей
WO2015053407A1 (ja) * 2013-10-08 2015-04-16 第一三共株式会社 抗ｆｇｆｒ２抗体と他剤の組合せ
US10780182B2 (en) 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
CN106470736B (zh) 2014-05-13 2021-05-28 宾夕法尼亚州大学信托人 包括表达双抗体构建体的aav的组合物及其用途
WO2015191986A1 (en) 2014-06-13 2015-12-17 Genentech, Inc. Methods of treating and preventing cancer drug resistance
MX2017000378A (es) 2014-07-10 2017-08-25 Bioarctic Neuroscience Ab ANTICUERPOS DE UNION A PROTOFIBRILLAS BETA AMILOIDE (Aß) MEJORADOS.
CA2961439A1 (en) * 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3699290A1 (en) 2014-12-24 2020-08-26 F. Hoffmann-La Roche AG Therapeutic, diagnostic, and prognostic methods for cancer
KR20170137717A (ko) * 2015-02-19 2017-12-13 바이오클린 테라퓨틱스, 인크. 암의 치료를 위한 방법, 조성물, 및 키트
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
WO2016179568A1 (en) * 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
JP2018536682A (ja) 2015-12-11 2018-12-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｅｇｆｒ及び／またはｅｒｂｂ３遮断に耐性のある腫瘍の成長を低減または防止するための方法
AU2017239038B2 (en) 2016-03-22 2024-06-27 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
MA45328A (fr) * 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
MX2018016257A (es) 2016-07-07 2019-11-21 Therachon Sas Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos.
WO2018145120A1 (en) * 2017-02-06 2018-08-09 Bioclin Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
WO2018227023A1 (en) * 2017-06-07 2018-12-13 Silverback Therapeutics, Inc. Antibody construct conjugates
CA3094534A1 (en) * 2018-03-19 2019-09-26 Abeome Corporation High affinity neutralizing monoclonal antibodies to programmed death ligand 1 (pd-l1) and uses thereof
US20200277387A1 (en) * 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer
CN110272900B (zh) * 2019-04-19 2024-03-26 中国人民解放军陆军军医大学 用于制备骨骼发育异常猪模型的sgRNA及其应用
US20220267452A1 (en) * 2019-07-12 2022-08-25 Chugai Seiyaku Kabushiki Kaisha Anti-mutation type fgfr3 antibody and use therefor
JP2022553830A (ja) * 2019-11-05 2022-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎ末端ｓｃＦｖ多重特異性結合分子
EP4061847A4 (en) * 2019-11-18 2024-01-10 Board of Regents, The University of Texas System ANTI-B7-H3 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF
AU2021327387A1 (en) 2020-08-21 2023-05-04 Genzyme Corporation Fgfr3 antibodies and methods of use
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
CN114716548A (zh) * 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途
EP4323531A1 (en) 2021-04-12 2024-02-21 Affinia Therapeutics Inc. Recombinant aav for treatment of neural disease
WO2023113806A1 (en) 2021-12-16 2023-06-22 Affinia Therapeutics, Inc. Recombinant aav for treatment of neural disease
US20240226324A1 (en) 2021-04-27 2024-07-11 Generation Bio Co. Non-viral dna vectors expressing therapeutic antibodies and uses thereof
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
WO2023177655A1 (en) 2022-03-14 2023-09-21 Generation Bio Co. Heterologous prime boost vaccine compositions and methods of use
WO2024002154A1 (en) * 2022-06-28 2024-01-04 Genequantum Healthcare (Suzhou) Co., Ltd. Anti-fgfr3 antibody conjugate and medical use thereof
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
US20240158515A1 (en) * 2022-11-14 2024-05-16 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US510087A (en) 1893-12-05 Method of securing suspension-loops to the ends of hammock-bodies
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
JPS54109494A (en) 1978-02-16 1979-08-28 Teikoku Hormone Mfg Co Ltd Method of measuring antigennantibody reaction
US4307016A (en) * 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) * 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) * 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) * 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4683203A (en) 1984-04-14 1987-07-28 Redco N.V. Immobilized enzymes, processes for preparing same, and use thereof
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8426467D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
US4970198A (en) 1985-10-17 1990-11-13 American Cyanamid Company Antitumor antibiotics (LL-E33288 complex)
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5079233A (en) 1987-01-30 1992-01-07 American Cyanamid Company N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
US6384191B1 (en) 1989-07-06 2002-05-07 Regents Of The University Of California Receptors for fibroblast growth factors
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) * 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) * 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CN1068652A (zh) 1991-06-10 1993-02-03 基斯通国际集团公司 监测再循环控制***性能的方法和设备
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
IL100219A0 (en) 1991-12-02 1992-09-06 Yeda Res & Dev Variable region within fibroblast growth factor receptors that confers ligand specificity
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP0625200B1 (en) 1992-02-06 2005-05-11 Chiron Corporation Biosynthetic binding protein for cancer marker
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
DK0669836T3 (da) 1992-11-13 1996-10-14 Idec Pharma Corp Terapeutisk anvendelse af kimære og radioaktivt mærkede antistoffer og humant B-lymfocytbegrænset differentieringsantigen til behandling af B-cellelymfom
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994021813A1 (en) 1993-03-17 1994-09-29 The Whittier Institute For Diabetes And Endocrinology Monoclonal antibodies specific for fibroblast growth factor receptors, immunotoxins, and use thereof
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5639635A (en) * 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
DK0836380T3 (da) 1995-06-12 2002-04-22 Yeda Res & Dev FGF9 som en specifik ligand for FGFR3
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
WO1997038123A1 (en) 1996-04-05 1997-10-16 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US5869245A (en) 1996-06-05 1999-02-09 Fox Chase Cancer Center Mismatch endonuclease and its use in identifying mutations in targeted polynucleotide strands
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US6306591B1 (en) 1997-06-18 2001-10-23 Utah State University Screening for the molecular defect causing spider lamb syndrome in sheep
DE69830315T2 (de) 1997-06-24 2006-02-02 Genentech Inc., San Francisco Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2532910T3 (es) 1998-04-02 2015-04-01 Genentech, Inc. Variantes de anticuerpos y fragmentos de los mismos
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6849255B2 (en) * 1998-08-18 2005-02-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for enhancing cartilage repair
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
IL128380A0 (en) 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
US7135311B1 (en) * 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
CA2388245C (en) 1999-10-19 2012-01-10 Tatsuya Ogawa The use of serum-free adapted rat cells for producing heterologous polypeptides
DE60030323T2 (de) 1999-12-24 2007-10-11 Genentech, Inc., South San Francisco Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
IL139380A0 (en) * 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
AU2002235202A1 (en) 2000-12-18 2002-07-01 Gene Logic, Inc. Treatment of bone disorders by modulation of fgfr3
WO2002087618A1 (fr) 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
DE60233509D1 (de) * 2001-06-20 2009-10-08 Fibron Ltd Fgfr3 blockierende antikörper, verfahren zum screening darauf und verwendungen davon
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED CELL CYTOTOXICITY DEPENDENT OF ANTIBODIES
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003084569A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition anticorps
CA2481657A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
US20040132140A1 (en) * 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US7749753B2 (en) * 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
WO2003084570A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1572744B1 (en) 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
US8124331B2 (en) 2003-03-26 2012-02-28 Progenika Biopharma, S.A. In vitro method to detect bladder transitional cell carcinoma
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
IL156495A0 (en) 2003-06-17 2004-01-04 Prochon Biotech Ltd Use of fgfr3 antagonists for treating t cell mediated diseases
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
KR101520209B1 (ko) 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
PL1773885T3 (pl) 2004-08-05 2010-09-30 Genentech Inc Humanizowani antagoniści anty c-met
CA2595398A1 (en) 2004-11-04 2006-05-11 Fibron Limited Treatment of b-cell malignancies
TW200902555A (en) * 2005-01-03 2009-01-16 Hoffmann La Roche Antibodies against IL-13 receptor alpha 1 and uses thereof
SG155947A1 (en) 2005-06-20 2009-10-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
PL1940844T3 (pl) 2005-10-28 2010-03-31 Irm Llc Związki i kompozycje jako inhibitory kinazy białkowej
DK1973950T3 (en) 2006-01-05 2014-12-15 Genentech Inc ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
JP5378202B2 (ja) 2007-03-15 2013-12-25 株式会社リバース・プロテオミクス研究所 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー
ES2556214T3 (es) 2007-11-12 2016-01-14 U3 Pharma Gmbh Anticuerpos para AXL
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
EP2324055A2 (en) 2008-08-25 2011-05-25 Amplimmune, Inc. Pd-1 antagonists and methods of use thereof
AR073770A1 (es) * 2008-10-20 2010-12-01 Imclone Llc Anticuerpo aislado que se enlaza especificamente con, e induce la degradacion del receptor-3 del factor de crecimiento del fibroblasto humano (fgfr-3), fragmento de enlace fgfr-3 humano del mismo, composicion farmaceutica y producto que lo comprenden
HUE061117T2 (hu) 2009-03-25 2023-05-28 Genentech Inc Anti-FGFR3 antitestek és eljárások alkalmazásukra
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
EP2743657B1 (en) 2012-12-13 2016-03-02 Thomson Licensing Method for controlling an image display device to allow an observer to perceive colours as another observer
TWI685349B (zh) 2013-07-16 2020-02-21 建南德克公司 利用ｐｄ-１軸結合拮抗劑及ｔｉｇｉｔ抑制劑治療癌症之方法
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
KR20170137717A (ko) 2015-02-19 2017-12-13 바이오클린 테라퓨틱스, 인크. 암의 치료를 위한 방법, 조성물, 및 키트
WO2017134412A1 (en) 2016-02-04 2017-08-10 Milan Momcilo Popovich Holographic waveguide optical tracker
WO2018145120A1 (en) 2017-02-06 2018-08-09 Bioclin Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer
US20200277387A1 (en) 2019-03-01 2020-09-03 Rainier Therapeutics, Inc. Methods and compositions for treating cancer

Also Published As

Publication number Publication date
UA104459C2 (uk) 2014-02-10
US9499623B2 (en) 2016-11-22
HRP20221471T1 (hr) 2023-02-03
KR101822663B1 (ko) 2018-01-29
HRP20150965T1 (hr) 2015-11-06
US20130287776A1 (en) 2013-10-31
RU2568066C2 (ru) 2015-11-10
HK1167666A1 (en) 2012-12-07
CA2754163C (en) 2019-04-09
SI3702371T1 (sl) 2023-01-31
US8710189B2 (en) 2014-04-29
CA2754163A1 (en) 2010-09-30
US11401333B2 (en) 2022-08-02
CN102378767A (zh) 2012-03-14
HUE061117T2 (hu) 2023-05-28
EP2679600A1 (en) 2014-01-01
US20170158769A1 (en) 2017-06-08
ES2549769T3 (es) 2015-11-02
US20100247531A1 (en) 2010-09-30
MA33208B1 (fr) 2012-04-02
ES2932874T3 (es) 2023-01-27
KR101830024B1 (ko) 2018-02-19
ECSP11011417A (es) 2011-11-30
AU2010229994B2 (en) 2016-08-18
US10287356B2 (en) 2019-05-14
CN102378767B (zh) 2015-01-14
DK2411414T3 (en) 2015-10-05
IL214433A0 (en) 2011-09-27
DK3702371T3 (da) 2022-11-28
AR075939A1 (es) 2011-05-04
IL214433A (en) 2017-02-28
EP3702371B1 (en) 2022-11-02
KR20110129976A (ko) 2011-12-02
US20160168250A1 (en) 2016-06-16
BRPI1006448B1 (pt) 2021-08-17
US20130046078A1 (en) 2013-02-21
US20140187754A1 (en) 2014-07-03
EP3702371A1 (en) 2020-09-02
SI2411414T1 (sl) 2016-01-29
BRPI1006448A2 (pt) 2020-08-18
ZA201105574B (en) 2012-10-31
WO2010111367A1 (en) 2010-09-30
CO6450665A2 (es) 2012-05-31
EP2411414B1 (en) 2015-07-15
US10000571B2 (en) 2018-06-19
JP2012521759A (ja) 2012-09-20
US8410250B2 (en) 2013-04-02
HUE025726T2 (en) 2016-04-28
AR119754A2 (es) 2022-01-12
TW201038283A (en) 2010-11-01
AU2010229994A1 (en) 2011-09-08
TWI507205B (zh) 2015-11-11
KR20160135854A (ko) 2016-11-28
US20170204188A1 (en) 2017-07-20
JP5757534B2 (ja) 2015-07-29
EP2411414A1 (en) 2012-02-01
MX345909B (es) 2017-02-22
NZ594339A (en) 2013-06-28
IL250624A0 (en) 2017-04-30
CN104788564A (zh) 2015-07-22
LT3702371T (lt) 2023-01-10
MX2011009961A (es) 2011-10-06
US20100291114A1 (en) 2010-11-18
SG174904A1 (en) 2011-11-28
US9161977B2 (en) 2015-10-20
RU2011142905A (ru) 2013-04-27
IL250624B (en) 2018-02-28
US20120321606A1 (en) 2012-12-20
US20190330355A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
PE20120553A1 (es) Anticuerpos anti-fgfr3
ES2628108T3 (es) Anticuerpos multiespecíficos
PH12018500708A1 (en) Humanized anti-human cd19 antibodies and methods of use
RS53942B1 (en) Antibodies and Immunoconjugates and Their Use
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20170935A1 (es) Anticuerpos anti-her2 e inmunoconjugados
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
PE20120877A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
PE20120878A1 (es) ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
NZ592119A (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
NZ586047A (en) Anti-vascular endothelial growth factor antibodies
PE20170670A1 (es) Anticuerpos anti-cll-1 e inmunoconjugados
PE20150211A1 (es) Anticuerpos e inmunoconjugados anti-cd79b
PE20141114A1 (es) Anticuerpos anti-mesotelina e inmunoconjugados
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
PE20141562A1 (es) Anticuerpos anti-htra1 y metodos de uso
PE20120539A1 (es) Anticuerpos anti-her biespecifico
RU2019125027A (ru) Афукозилированные антитела к рецептору фактора роста фибробластов fgfr2iiib
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
EP4252769A3 (en) Anti-complement factor c1q antibodies and uses thereof
RS52305B (en) ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE
RU2017128882A (ru) Антитела к биотину и способы их применения
NZ602040A (en) Anti-lrp6 antibodies
NZ597251A (en) Antibodies and immunoconjugates and uses therefor
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados

Legal Events

Date Code Title Description
FC Refusal